Compare LINC & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LINC | LXEO |
|---|---|---|
| Founded | 1946 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 732.0M | 663.5M |
| IPO Year | 2005 | 2023 |
| Metric | LINC | LXEO |
|---|---|---|
| Price | $21.77 | $9.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $26.67 | $18.22 |
| AVG Volume (30 Days) | 261.2K | ★ 1.0M |
| Earning Date | 11-10-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.12 | N/A |
| EPS | ★ 0.45 | N/A |
| Revenue | ★ $494,742,000.00 | N/A |
| Revenue This Year | $17.79 | N/A |
| Revenue Next Year | $9.23 | N/A |
| P/E Ratio | $49.71 | ★ N/A |
| Revenue Growth | ★ 16.90 | N/A |
| 52 Week Low | $14.10 | $1.45 |
| 52 Week High | $25.76 | $10.38 |
| Indicator | LINC | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 55.57 | 55.69 |
| Support Level | $20.25 | $9.27 |
| Resistance Level | $22.71 | $10.04 |
| Average True Range (ATR) | 0.96 | 0.61 |
| MACD | 0.24 | -0.04 |
| Stochastic Oscillator | 74.50 | 70.17 |
Lincoln Educational Services Corp provides diversified career-oriented post-secondary education to high school graduates and working adults. The company offers programs in automotive technology, skilled trades, healthcare services, hospitality services, and business and information technology. Its reportable segments include; Campus Operations, and Transitional. The majority of the revenue is generated from the Campus Operations segment which includes all campuses that are continuing in operation and contribute to the Company's core operations and performance.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.